The anaplastic lymphoma kinase (ALK) gene is a member of the insulin receptor superfamily and it has been linked with more than twenty distinct chimera that include established drivers of several human cancers. Non-small-cell lung carcinoma (NSCLC) is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. The market is witnessing strong growth due to high awareness among the population through government initiatives. Furthermore, the drugs for NSCLC are given swift approvals by regulatory bodies and fundings for research. This has led to a new generation of drugs being introduced in the NSCLC market. The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, anaplastic lymphoma kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors.
Global Anaplastic Lymphoma Kinase Inhibitors Market: Dynamics
Growth of Bio-pharmaceutical Industries and Increasing Strategic Collaborations Boosting Market
Increase in number of strategic collaborations between manufacturers and research institutes along with rapidly growing health care and pharmaceutical industries in developed and developing economies are some factors that are anticipated to assist the global anaplastic lymphoma kinase inhibitors market during the forecast period.
To Know the Segments Analyzed in the Anaplastic Lymphoma Kinase Inhibitors Market Report, Ask for a Brochure here
In 2017, Novartis AG entered into strategic agreement with Wyss Institute at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for immuno-oncology therapies.
Increase in Health Care Expenditure Boosting Market
Emerging economics such as India, China, Brazil, Malaysia, and other emerging countries in developing regions such as Asia Pacific, Middle East & Africa, and Latin America offer numerous opportunities in health care sector. Increased government expenditure in health care segment is likely to pace up the expansion of anaplastic lymphoma kinase inhibitors market during the forecast period. For instance, according to the Union Budget 2017-18, in India, the total health care expenditure was increased from 1.97% to 2.27% of total Union Budget.
Increasing Prevalence of NSCLC
Increase in number of patients throughout the world in developing as well as developed economies is anticipated to increase the demand for therapeutics and is expected to drive the global anaplastic lymphoma kinase inhibitors market during the forecast period. For instance, in 2018, approximately 2.1 million new cases of lung cancer were diagnosed across the globe. Lung cancer records the highest mortality rate among developing countries compared to all type of cancers, with developed regions such as North America and Europe ensuring the highest rates.
Global Anaplastic Lymphoma Kinase Inhibitors Market: Competitive Landscape
Major players operating in the global anaplastic lymphoma kinase inhibitors market include F. Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG, Oncoethix GmbH, Pfizer, Inc., and Takeda Pharmaceutical Co., Ltd.
To Know More about TMRs Unique Offerings for Anaplastic Lymphoma Kinase Inhibitors Market, Request a Custom Report here
Hoffman-La Roche Ltd.
Hoffmann-La Roche Ltd. (Roche) is a leading global health care and biotech company that engages in development and marketing of pharmaceuticals, biopharmaceuticals, and In Vitro Diagnostic (IVD) devices & consumables. The company operates through two divisions: Pharmaceuticals and Diagnostics. Its pharmaceuticals business segment provides therapies in the field of oncology, immunology, neuroscience, ophthalmology, infectious diseases, and others. Roche, which also offers diagnostic solutions for oncology and other chronic diseases, has built an expertise in cancer biomarker identification and biological drugs. This has boosted the company’s oncology portfolio.
Pfizer Inc. is a leading biopharmaceutical company that is focused on discovery, development, manufacturing, and commercialization of health care products. Its portfolio includes consumer health care products, vaccines, and medicines. Pfizer operates through two key business segments: Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). Under the Innovative Health segment, the company offers branded oncology and other therapy drugs, while it offers biosimilars for oncology and other indications under the Essential Health segment. Pfizer offers oncology drugs across therapy lines, such as antibody drug conjugate, monoclonal antibodies, and kinase inhibitors.
Global Anaplastic Lymphoma Kinase Inhibitors Market: Segmentation
The global anaplastic lymphoma kinase inhibitors market can be segmented based on:
In terms of type, the anaplastic lymphoma kinase inhibitors market can be classified into:
- Second-generation ALK inhibitors
- First-generation ALK inhibitors
- Third-generation ALK inhibitors
In terms of region, the global anaplastic lymphoma kinase inhibitors market can be segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East & Africa (MEA)
North America accounted for the dominant share of the global anaplastic lymphoma kinase inhibitors market in 2018 owing to the presence of modern health care infrastructure and an efficient U.S. government system. However, Asia Pacific is expected to expand at the highest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and increasing number of government projects related to lung, cancer and their respective interventions would boost the market in APAC during the forecast period.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.